Article Text

See original article:

Download PDFPDF


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The department of one of the authors who co-authored all of the below papers has found that the affi liations were not correct. The correct affiliations for Professor P Emery, for all of the below articles, are: 1Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK.

1. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216–21.

2. Doward LC, McKenna SP, Whalley D, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 2009;68:196–200.

3. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-TNF response in RA. Ann Rheum Dis 2009;68:69–74.

4. Smolen JS, Han C, van der Heijde DM, et al.; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823–7.

5. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220–7.

6. Emery P, Van Vollenhoven R, Ostergaard M, et al. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis 2009;68:456–9.

7. Bejarano V, Conaghan PG, Proudman SM, et al. Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis. Ann Rheum Dis 2009;68:761–3.

8. Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009;68:770–6.

9. Bennett AN, Marzo-Ortega H, Emery P, et al.; Leeds Spondyloarthropathy Group. Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stage. Ann Rheum Dis 2009;68:765–7.

10. Marzo-Ortega H, McGonagle D, O'Connor P, et al. Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 2009;68:1721–7.

11. Gilworth G, Emery P, Gossec L, et al. Adaptation and cross-cultural validation of the rheumatoid arthritis work instability scale (RA-WIS). Ann Rheum Dis 2009;68:1686–90.

12. Gilworth G, Emery P, Gossec L, et al. Adaptation and cross-cultural validation of the RA-WIS (Work Instability Scale). Ann Rheum Dis 2009;68:1686–90.

13. Jarrett SJ, Sivera F, Cawkwell LS, et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009;68:1466–9.

14. Haugeberg G, Conaghan PG, Quinn M, et al. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009;68:1898–901.

15. Genovese MC, Breedveld FC, Emery P, et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:1894–7.

16. Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010;69:222–5.

17. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl 1):i2–29.

18. Freeston JE, Wakefield RJ, Conaghan PG, et al. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis 2010;69:417–9.

19. Jones E, Churchman SM, English A, et al. Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level. Ann Rheum Dis 2010;69:450–7.

20. Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2010;69:364–7.

21. Machold KP, Landewé R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 2010;69:495–502.

22. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638–43.

23. Smolen JS, Aletaha D, Bijlsma JW, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

24. Burr ML, Naseem H, Hinks A, et al.; BIRAC Consortium; YEAR Consortium. PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Ann Rheum Dis 2010;69:666–70.

25. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510–16.

26. Bennett AN, Rehman A, Hensor EM, et al. The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. Ann Rheum Dis 2010;69:891–4.

27. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976–86.

28. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.

29. Tan RJ, Gibbons LJ, Potter C, et al.; BRAGGSS. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 2010;69:1029–35.

30. Robinson JI, Barrett JH, Taylor JC, et al.; YEAR Consortium; BRAGGSS. Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Ann Rheum Dis 2010;69:1054–7.

31. Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158–61.

32. Haugeberg G, Bennett AN, McGonagle D, et al. Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational study. Ann Rheum Dis 2010;69:1364–6.

33. Schoels M, Aletaha D, Smolen JS, et al. Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis 2010;69:575–8.

34. Eyre S, Flynn E, Martin P, et al. No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. Ann Rheum Dis 2010;69:1407–8.

35. Eyre S, Hinks A, Flynn E, et al. Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. Ann Rheum Dis 2010;69:1572–3.

36. Orozco G, Eyre S, Hinks A, et al.; Wellcome Trust Case Control consortium YEAR Consortium. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Ann Rheum Dis 2010;69:813–16.

37. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510–16.

38. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636–42.

39. Barkham N, Coates LC, Keen H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010;69:1926–8.

40. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629–35.

41. Dixon WG, Hyrich KL, Watson KD, et al.; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086–91.

View Abstract

Linked Articles